Immunocore Holdings plc (IMCR)

Market Cap	1.48B
Revenue (ttm)	310.20M
Net Income (ttm)	-51.09M
Shares Out	50.08M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,598
Open	30.20
Previous Close	30.13
Day's Range	29.31 - 30.50
52-Week Range	27.19 - 66.00
Beta	0.80
Analysts	Buy
Price Target	63.00 (+112.98%)
Earnings Date	May 7, 2025

About IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 493
• Stock Exchange: NASDAQ
• Ticker Symbol: IMCR
• Website: https://www.immunocore.com

Financial Performance

In 2024, Immunocore Holdings's revenue was $310.20 million, an increase of 24.37% compared to the previous year's $249.43 million. Losses were -$51.09 million, -7.60% less than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is $63.0, which is an increase of 112.98% from the latest price.

Price Target

$63.0

(112.98% upside)

Analyst Consensus: Buy